Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study

NCT04745832 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT04745832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04745832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME- 401) in Combination With Rituximab Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non Hodgkin's Lymphoma (iNHL) - The COASTAL Study
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 13, 2021
Completion date
March 20, 2023
Enrollment
82 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma (fl), marginal zone lymphoma, non hodgkin lymphoma